Pricing, Reimbursement, and Patient Support Services Strategy for a New Oncology Injectable Therapy

A leading biotech company was preparing to launch a new injectable oncology therapy that has to be administered by a healthcare professional.  Its leaders needed to understand the therapy’s pricing and reimbursement situation vs relevant competitors.  In addition, they needed to assess the potential HCP reimbursement support needs and patient support needs related to cost differences between the new therapy and competitors.

After completing secondary pricing research, our team identified potential risks and opportunities for the client’s patient support team, driven by pricing differential and both HCP and patient support needs.  We then facilitated a group working session with the patient support team to review this assessment and align on potential strategies.  Next, we synthesized outputs from the secondary research and working session into a comprehensive report. This report summarized our pricing assessment, reimbursement risks and support needs for HCPs and patients, and strategic recommendations to address potential risks.

Blue Matter helped socialize the strategic recommendations with key leaders within the organization, assisting the patient support team in securing buy-in and cross-functional alignment on the launch plan.  As a result of our work, the client was prepared to advance its patient support recommendation and investment to key internal leadership stakeholders.